Research ExplorerPublicationsCurrent understandings in treating children with steroid-res...

Current understandings in treating children with steroid-resistant nephrotic syndrome

Standard

Current understandings in treating children with steroid-resistant nephrotic syndrome. / Lee, Jiwon M; Kronbichler, Andreas; Shin, Jae Il; Oh, Jun.

In: PEDIATR NEPHROL, Vol. 36, No. 4, 04.2021, p. 747-761.

Research output: SCORING: Contribution to journal › SCORING: Review article › Research

Harvard

Lee, JM, Kronbichler, A, Shin, JI & Oh, J 2021, 'Current understandings in treating children with steroid-resistant nephrotic syndrome', PEDIATR NEPHROL, vol. 36, no. 4, pp. 747-761. https://doi.org/10.1007/s00467-020-04476-9

APA

Lee, J. M., Kronbichler, A., Shin, J. I., & Oh, J. (2021). Current understandings in treating children with steroid-resistant nephrotic syndrome. PEDIATR NEPHROL, 36(4), 747-761. https://doi.org/10.1007/s00467-020-04476-9

Vancouver

Lee JM, Kronbichler A, Shin JI, Oh J. Current understandings in treating children with steroid-resistant nephrotic syndrome. PEDIATR NEPHROL. 2021 Apr;36(4):747-761. https://doi.org/10.1007/s00467-020-04476-9

Bibtex

@article{f73086460509425aa7a88510bf413179,
title = "Current understandings in treating children with steroid-resistant nephrotic syndrome",
abstract = "Steroid-resistant nephrotic syndrome (SRNS) remains a challenge for paediatric nephrologists. SRNS is viewed as a heterogeneous disease entity including immune-based and monogenic aetiologies. Because SRNS is rare, treatment strategies are individualized and vary among centres of expertise. Calcineurin inhibitors (CNI) have been effectively used to induce remission in patients with immune-based SRNS; however, there is still no consensus on treating children who become either CNI-dependent or CNI-resistant. Rituximab is a steroid-sparing agent for patients with steroid-sensitive nephrotic syndrome, but its efficacy in SRNS is controversial. Recently, several novel monoclonal antibodies are emerging as treatment option, but their efficacy remains to be seen. Non-immune therapies, such as angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers, have been proven efficacious in children with SRNS and are recommended as adjuvant agents. This review summarizes and discusses our current understandings in treating children with idiopathic SRNS.",
author = "Lee, {Jiwon M} and Andreas Kronbichler and Shin, {Jae Il} and Jun Oh",
year = "2021",
month = apr,
doi = "10.1007/s00467-020-04476-9",
language = "English",
volume = "36",
pages = "747--761",
journal = "PEDIATR NEPHROL",
issn = "0931-041X",
publisher = "Springer",
number = "4",

}

RIS

TY - JOUR

T1 - Current understandings in treating children with steroid-resistant nephrotic syndrome

AU - Lee, Jiwon M

AU - Kronbichler, Andreas

AU - Shin, Jae Il

AU - Oh, Jun

PY - 2021/4

Y1 - 2021/4

N2 - Steroid-resistant nephrotic syndrome (SRNS) remains a challenge for paediatric nephrologists. SRNS is viewed as a heterogeneous disease entity including immune-based and monogenic aetiologies. Because SRNS is rare, treatment strategies are individualized and vary among centres of expertise. Calcineurin inhibitors (CNI) have been effectively used to induce remission in patients with immune-based SRNS; however, there is still no consensus on treating children who become either CNI-dependent or CNI-resistant. Rituximab is a steroid-sparing agent for patients with steroid-sensitive nephrotic syndrome, but its efficacy in SRNS is controversial. Recently, several novel monoclonal antibodies are emerging as treatment option, but their efficacy remains to be seen. Non-immune therapies, such as angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers, have been proven efficacious in children with SRNS and are recommended as adjuvant agents. This review summarizes and discusses our current understandings in treating children with idiopathic SRNS.

AB - Steroid-resistant nephrotic syndrome (SRNS) remains a challenge for paediatric nephrologists. SRNS is viewed as a heterogeneous disease entity including immune-based and monogenic aetiologies. Because SRNS is rare, treatment strategies are individualized and vary among centres of expertise. Calcineurin inhibitors (CNI) have been effectively used to induce remission in patients with immune-based SRNS; however, there is still no consensus on treating children who become either CNI-dependent or CNI-resistant. Rituximab is a steroid-sparing agent for patients with steroid-sensitive nephrotic syndrome, but its efficacy in SRNS is controversial. Recently, several novel monoclonal antibodies are emerging as treatment option, but their efficacy remains to be seen. Non-immune therapies, such as angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers, have been proven efficacious in children with SRNS and are recommended as adjuvant agents. This review summarizes and discusses our current understandings in treating children with idiopathic SRNS.

U2 - 10.1007/s00467-020-04476-9

DO - 10.1007/s00467-020-04476-9

M3 - SCORING: Review article

C2 - 32086590

VL - 36

SP - 747

EP - 761

JO - PEDIATR NEPHROL

JF - PEDIATR NEPHROL

SN - 0931-041X

IS - 4

ER -